CD8A and neoplasm: EZM2302 treatment increased blood (Supplementary Figure S5E) and local tumor infiltrating CD8+ T cells (Figure 5L) as compared with vehicle treatment after 30 days, although the effects did not reach statistical significance at the earlier time points.